Inotiv Inc., a company that breeds dogs and imports monkeys for pharmaceutical research, has filed for bankruptcy protection. The Indiana-based firm supplies laboratory animals to drug developers running preclinical experiments, placing it at a critical junction in the pharmaceutical supply chain.

Two regulatory pressures drove the collapse. Tighter rules governing Inotiv's US canine breeding operations squeezed that revenue stream, while tariffs imposed on non-human primates raised in China inflated costs for its monkey import business. Together, these headwinds eroded the company's financial foundation beyond recovery.

For pharmaceutical companies, the bankruptcy raises immediate questions about securing laboratory animals for ongoing drug trials. Dogs and non-human primates remain essential for certain stages of preclinical testing, and Inotiv's exit reduces an already concentrated supplier market. Competitors in the contract research and animal breeding space could see increased demand as clients scramble for alternatives.

The filing also illustrates how trade policy and domestic regulation can compound to destabilize niche industries. Companies reliant on imported research animals face a tariff environment that shows no signs of easing, while domestic breeders confront mounting scrutiny over animal welfare standards. Inotiv's collapse is a case study in how specialized biomedical supply businesses sit exposed to policy shifts on multiple fronts simultaneously.